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Abstract. The 28th Joint Conference of the Parasitic Diseases Panels of the U.S.-Japan
Cooperative Medical Sciences Program held in Baltimore, Maryland focused on current
research within both countries on antiparasitic chemotherapy. This meeting report sum
marizes presentations of work in progress on antiparasitic drugs currently in use and drugs
under development or in clinical trials, as well as reports on potentially unique parasite
characteristics that may provide targets for development of future therapeutics.
as well as other members of the research com
munity within the U.S., Japan, and other South
east Asian countries. These meetings are open
to the public.
The 28th Joint Conference of the Parasitic
Diseases Panels of the U.S.-Japan Cooperative
Medical Science Program was held in Baltimore,
Maryland July on 19â€”22, 1993. It covered as
pects of the immunology, cell biology, epide
miology, and vector biology of malaria, schis
tosomiasis, filanasis and trypanosomes. This
report summarizes the discussions from a mini
symposium on antiparasitic chemotherapy,
which was a major focus of the conference.
DRUGS IN CURRENT USE
Artemisinin. Derivatives of artemisinin are
used widely because they are one of the few
effective treatments for multi-drug resistant
Plasmodium falciparum malaria. Understanding
the mechanism of artemisinin action may aid in
the development of better second generation
drugs. Data presented by Steve Meshnick from
the University of Michigan (Figure 1) suggest
that artemisinin has a two step mechanism of
action.'-3 First, the drug interacts with intrapar
asitic heme that catalyzes its conversion into a
free radical. Second, the free radical form of the
drug alkylates critical malarial proteins. Evi
dence for the first step is based on electron spin
resonance spectroscopy and cyclic voltammetry
studies that demonstrate that heme can catalyze
The U.S.-Japan Cooperative Medical Sciences
Program was established in 1965 by joint agree
ment of the President of the United States and
the Prime Minister of Japan. The bilateral pro
gram was organized to promote cooperative re
search on health problems of recognized impor
tance in Southeast Asia. Parasitic disease was
one of the five original areas selected for collab
orative research at that time. Currently, other
Panels affiliated with the Program include chol
era, leprosy, tuberculosis, viral diseases, hepati
tis, malnutrition, environmental mutagenesis and
carcinogenesis, and the acquired immunodefi
ciency syndrome (AIDS). There is also an im
munology board intended to provide expertise in
this fundamental area of research. The first char
ter of scientific guidelines to the Parasitic Dis
eases Panel specified that the research concerns
be confined to schistosomiasis and filariasis,
mainly due to their important impact on world
health and economic development. In 1985,
however, the guidelines were expanded and re
search on malaria and other vector-borne para
sitic diseases was incorporated into the program.
Annual conferences are held alternatively in the
U.S. and Japan. Participants include members of
the U.S. and Japanese Parasitic Diseases Panels
* Editor's footnote: The publication of this meeting
report is a departure from the usual format for material
appearing in the Journal. Citation of specific infor
mation included herein must refer to the original ref
erence. This report is not a citable document.
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Malaria target proteins
FIGURE 1. Proposed two step mechanism of action of artemisinin. First, the drug interacts with intraparasitic
heme that catalyzes its conversion into a free radical. Second, the free radical form of the drug alkylates critical
malarial proteins.
the opening of the drug's endoperoxide bridge.
The fact that iron chelators and free radical scav
engers antagonize the antiplasmodial activity of
artemisinin in vitro suggests that heme-induced
degradation of the endoperoxide bridge may be
important in vivo. Evidence for the second al
kylation step is based on two observations: 1)
alkylation of human serum albumin by artemi
5mmin vitro,and 2) sodiumdodecylsulfategel
autoradiograms that demonstrate the alkylation
of parasite proteins by radiolabeled drug.
Studies presented by Mamoru Suzuki from
Gunma University suggest that artemether has a
rapid onset of action in vivo in P. falciparum
infected Aotus monkeys.4 Distinct morphologic
changes were seen within 2 hr and viable para
sites disappeared within 66 hr, although dead in
traerythrocytic parasites persisted in the circu
lation for up to 10 days. Ultrastructural studies
showed marked swelling and disruption of the
inner membrane of parasite mitochondria within
2 hr. Late changes included clumping of ribo
somes and the appearance of electron dense ma
terial in the nucleus. Together these observations
suggest that mitochondria, which contain many
hemoproteins, may be an important target for
artemisinin. If this hypothesis is correct, addi
tional information will be required to explain the
specificity of artemisinin, i.e., why are the ar
temisinin concentrations that inhibit parasite
growth by damaging their mitochondria not tox
ic also for mammalian cells at those concentra
tions?
Dihydrofolate reductase (DHFR) inhibi
tors. Toshihiro Hon from Osaka University has
used a novel approach to study the action of
DHFR inhibitors against the P. falciparum
DHFR in vitro. To circumvent problems asso
ciated with the expression of AT-rich parasite
DNA in Escherichia coli, he synthesized an ar
tificial P. falciparum DHFR gene in vitro using
characteristic E. coli codons to produce the de
sired amino acid sequence of the parasite
DHFR.5 Expression of this construct in E. coli
yielded -â€˜-30%of cell protein as the parasite
DHFR. Because most of the parasite DHFR was
in aggregates, it did not demonstrate enzymatic
activity. However, after solubilization and ren
aturation, the enzymatic activity, K11,,and V,,,,,
of the parasite DHFR were similar to those of
the purified bifunctional P. falciparum DHFR
thymidylate synthase complex,6 and K@svalues
were similar to those obtained previously with
known inhibitors. This recombinant parasite en
zyme is now being used to test candidate DHFR
inhibitors in vitro.
Single-dose diethylcarbamazine (DEC) ver
sus ivermectin. In previous studies, DEC has
been given in doses of 50â€”100 mg three times a
day for up to 21 days, and has frequently pro
duced severe limiting side effects. In contrast,
ivermectin has been given as a single dose every
6â€”12months and has had a much lower inci
dence of side effects. James Kazura from Case
Western Reserve University reported a study
from Papua New Guinea in which single doses
of DEC and ivermectin were compared in per
sons with bancroftian filariasis. Although the ini
tial decrease in microfilaremia was greater in the
ivermectin group, the results with DEC and iver
mectin were similar at 90 and 180 days. Most
remarkable was the relative absence of severe
side effects with single dose DEC. These results
suggest that it may be possible to give DEC as
a single dose without the severe side effects ob
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DRUGS UNDER DEVELOPMENT OR IN
CLINICAL TRIALS
Desferrioxamine (DFO). Data presented by
Masamichi Aikawa and Gary Brittenham from
Case Western Reserve University suggest that
iron-chelating agents such as DFO may offer a
Hâ€¢me new approach to the treatment of cerebral ma
laria by inhibiting both parasite growth and per
oxidant damage to host cells. Parasite growth is
inhibited by DFO in vitro, presumably because
DFO chelates the iron that the parasite needs to
make iron-containing enzymes such as ribonu
cleotide reductase. This hypothesis is also con
sistent with morphologic studies that demon
strated nuclear abnormalities as the earliest
ultrastructural changes in parasites treated with
DFO)' Results of a clinical trial indicate that
DFO reduced the median duration of deep coma
from 68 to 24 hr in children with cerebral ma
laria, all of whom were treated with quinine, and
simultaneously increased the rate of parasite
clearance.'2 The variety of iron-chelating agents
available raises the possibility that these agents
may provide a new class of chemotherapeutic
agents for severe and cerebral malaria.
POTENTIALLY UNIQUE PARASITE TARGETS FOR
DRUG DEVELOPMENT
Hemoglobin degradation in Plasmodia. The
intraerythrocytic malaria parasite P. falciparum
internalizes and degrades most of its host ery
throcyte's hemoglobin. Data presented by Dan
iel Goldberg from Washington University (Fig
ure 2) indicate that the critical first step in
hemoglobin degradation is cleavage of the a
chain by an aspartic protease between residues
33 (Phe) and 34 (Leu).'3 Examination of multi
ple hemoglobin sequences has shown that this
cleavage site is retained in all known human he
moglobins. The gene for this enzyme has now
been cloned and found to be homologous to hu
man renin and cathepsin D, although it has an
unusually long propiece with a hydrophobic re
gion consistent with a membrane spanning do
main. The second enzyme involved in the pro
teolysis of hemoglobin is an unusual cysteine
protease that appears to function only after the
initial aspartic protease cleavage. These results
suggest that the proteolysis of hemoglobin by
plasmodia is a highly ordered process,'4 and that
it may be possible to design specific inhibitors
FIGuRE 2. Proposed mechanism of hemoglobin ca
tabolism in Plasmodium falciparum. AH I and H are
aspartic hemoglobinases I and II; Cys is the cysteine
protease; HP is heme polymerase; Exo is a proposed








dose DEC may produce antiparasitic effects sim
ilar to those obtained with 14-21-day courses of
DEC.7'8
Effect of ivermectin on transmission of
onchocerciasis. Ivermectin markedly reduces
the number of microfilariae in the skin of per
sons with onchocerciasis. In a prospective study
carried out in Guatemala, Edward Cupp from the
University of Arizona reported that ivermectin
also reduced the transmission of onchocerciasis.
In a three-year study, four six-monthly treat
ments with ivermectin reduced both the preva
lence and intensity of microfilarial infection in
the black fly vector.9 This change was associated
with an 80â€”100% reduction in transmission as
measured by a decrease in the numbers of in
fective stage larvae in the Simulium ochraceum.
Repetitive treatment cycles also affected adult
worms, increasing the proportions of uninsemi
nated, damaged, and dead female worms in sub
cutaneous nodules.'Â° These results are consistent
with a direct drug effect on adult male and fe
male worms in vivo.
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of this process that have antiplasmodial activity
both in vitro and in vivo.
Topoisomerase II in trypanosomes The mi
tochondrial (kinetoplastid or k) DNA of the try
pansosomes that cause African sleeping sickness
contains thousands of interlocked maxi-(--'-20
kb) and mini-(--- 1 kb) circles that must undergo
many changes during replication and transcrip
tion. These reactions are catalyzed by topoiso
merases, which are inhibited by a number of
drugs in current use as antitumor or antibacterial
agents: etoposide, adriamycin, amsacrine, nali
dixic acid, and the fluoroquinolones. Data pre
sented by Terry Shapiro from Johns Hopkins
University indicate that inhibitors of kinetoplast
topoisomerase II act in trypanosomes by stabi
lizing a cleavable complex between the enzyme
and its DNA substrate. Studies in Trypanosoma
equiperdum demonstrate that etoposide increas
es the concentration of cleavable complexes be
tween mitochondrial topoisomerase H and mm
icircle DNA in a time-dependent fashion. The
cleavage sites map to positions of importance in
minicircle replication)5' 16Conventional antitry
panosomal agents such as pentamidine and sa
morn also inhibit kinetoplast topoisomerase II
activity, and may act against trypanosomes in
part by this mechanism. These results support
the hypothesis that mitochondrial and nuclear to
poisomerase II activities are distinct; they sug
gest that kinetoplast topoisomerase II enzymes
may be important targets in the chemotherapy of
trypanosomiasis.
Thymidylate synthase in Plasmodia. Previ
ous studies by Pradip Rathod and his colleagues
at Catholic University (Washington, DC) have
shown that 5-fluoroorotic acid inhibits the
growth of P. falciparum in vitro'7 and P. yoelii
in vivo (unpublished data). More recent studies
indicate that the concentrations of 5-fluoroorotic
acid necessary to inhibit clonal viability of par
asites correlate well with those that inhibit thym
idylate synthase activity, and thus suggest that
the mechanism responsible for this effect is in
hibition of the parasite thymidylate synthase@
Ion channels in Plasmodia. Patch clamping,
which has generally been used with much larger
cells such as squid axons, has not been techni
cally feasible previously for either the parasite
or its host red blood cell (RBC). After removing
the intervening RBC membrane and forming gi
gaohm seals on the small (3â€”5p.m) parasite, Dc
sai and his colleagues were able to study trans
port across the parasitophorous vacuole
membrane (PVM), the outer of the two parasite
membranes. This approach identified a 140 pS
channel on the PVM, which is permeable to both
cations and anions, such as lysine@, Tris@,@
Mg@, and glucuronate.'9 This channel is pres
ent at high density and is open more than 98%
of the time at the resting potential of the PVM.
Together with a new Ca@+ pathway in the mem
brane of the RBC,2Â°these studies provide evi
dence for parasite-induced channels that are po
tentially unique chemotherapeutic targets.
Neither channel is affected by chloroquine, and
both are similar in chioroquine-susceptible and
-resistant parasites.
Proteases in schistosomes. James McKerrow
and his colleagues at the University of California
in San Francisco have performed a series of
studies on rationale drug design using computer
modeling of the schistosomal serine protease
that cercariae use to cross the skin and infect
humans.2' Based on x-ray diffraction data for
similar proteases that have been crystallized,
computer modeling was used to create a model
of the cercarial serine protease and to examine
the interaction with inhibitors using computer
graphics. Using this strategy, four of the 40 pu
tative inhibitors identified by computer modeling
were found to have K1s values < 100 pM and
are therefore being subjected to further study.22
These studies support the idea that specific in
hibitors of parasite enzymes that are effective in
vitro and in vivo can be developed with the as
sistance of computer modeling. Additional stud
ies with peptidomimetic inhibitors have con
firmed that cysteine proteases of Schistosoma
mansoni and Trypanosoma cruzi can be selec
tively inhibited in vitro and in vivo without tox
icity at concentrations that interrupt the parasite
life cycle.
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